PARK2, frequently mutated in glioma, acts as a tumor suppressor by boosting ubiquitination-dependent degradation of β-catenin, which results in attenuation of Wnt signaling (Veeriah et al., 2010; Lin et al., 2015). Here, PRKN is linked to central nervous system cancer.